Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 19/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 14/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 14/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.39 |
| ▸ | CHRNA10 | Q9GZZ6 | 7/20 | 0.36 |
| ▸ | CHRNA9 | Q9UGM1 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL584372 | 0.99 | CHRNA7 (0.38) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2327446 | 0.89 | CHRNB4 (0.30) | CHRNA7CHRNB4CHRNA3CHRNA10CHRNA9 | |
| Bromide SCHEMBL5014264 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL584419 | 0.88 | CYP3A4 (0.32) | CHRNB2CHRNA4CYP2D6 | |
| SCHEMBL21523874 | 0.85 | RARB (0.40) | KDM4EALDH1A1TP53CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL27856205 | 0.83 | RARB (0.38) | KDM4EALDH1A1TP53CYP1A2CYP2D6 | |
| SCHEMBL585087 | 0.83 | — | — | |
| SCHEMBL2328568 | 0.83 | LSS (0.37) | KDM4EALDH1A1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL585264 | 0.82 | LSS (0.36) | KDM4EALDH1A1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL29089950 | 0.82 | ATP4A (0.40) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | claimed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | claimed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| EP-2355816-A2 | NOVEL USES | Destiny Pharma Limited (GB) | 2011-08-17 | — | — | EP | claimed |
| WO-2010046663-A2 | NOVEL USES | DESTINY PHARMA LIMITED (GB) | 2010-04-29 | — | — | WO | claimed |
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262511-A1 | Novel Uses | XDH, F12, ZFX | CHRNA7 4821/4885CHRNB4 3758/4885CHRNA3 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.